Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Autonomic dysfunction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Autonomic dysfunction. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-022579-68 Sponsor Protocol Number: COR-1/02 Start Date*: 2011-08-16
    Sponsor Name:Corimmun GmbH
    Full Title: COR-1, an anti-ß1 receptor antibody cyclopeptide in heart failure: a phase II, multicentre, randomised, double-blind and placebo-controlled study with parallel groups
    Medical condition: Heart Failure, Dilated Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10056419 Dilated cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001430-40 Sponsor Protocol Number: 012-06 Start Date*: 2007-05-04
    Sponsor Name:University Hospital Department of Cardiology
    Full Title: Tiral of Invasive versus Medical therapy of Early coronary artery disease in Diabetes (TIME-DM)
    Medical condition: The prevalence of type II diabetes is increasing rapidly, contributing importantly to a new "epidemic" of coronary artery disease (CAD). Atherosclerosis accounts for 65-80% of all death among diabe...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001066-16 Sponsor Protocol Number: H23750 Start Date*: 2007-01-04
    Sponsor Name:John L. Berk, M.D.
    Full Title: The effect of diflunisal (IND 68092) on familial amyloidosis
    Medical condition: Familial Amyloid Polyneuropathy (FAP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003519-24 Sponsor Protocol Number: ALN-TTR02-008 Start Date*: 2019-03-12
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progressi...
    Medical condition: Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10019889 Hereditary neuropathic amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) PT (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018157-23 Sponsor Protocol Number: D0490C00014 Start Date*: 2010-11-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics ...
    Medical condition: Multiple system atrophy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064060 Multiple system atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003231-29 Sponsor Protocol Number: ATH434-201 Start Date*: 2022-07-26
    Sponsor Name:Alterity Therapeutics Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy
    Medical condition: Multiple System Atrophy (MSA)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000805-22 Sponsor Protocol Number: A20175CI03 Start Date*: 2021-09-28
    Sponsor Name:Neuroplast BV
    Full Title: A multi-center, double-blind, randomized, placebo-controlled, delayed- start phase II/III study to assess the efficacy and safety of Neuro-Cells in (sub)acute spinal cord injury patients
    Medical condition: Traumatic Spinal cord injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003525-30 Sponsor Protocol Number: COLCAD Start Date*: 2022-01-06
    Sponsor Name:Aarhus University Hospital, Steno Diabetes Center Aarhus
    Full Title: Effect of colchicine on cardiovascular target organ damage in patients with type 2 diabetes - A randomized placebo-controlled trial
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002231-18 Sponsor Protocol Number: RMHCAN1104 Start Date*: 2015-12-01
    Sponsor Name:University Southampton Hospital NHS Foundation Trust
    Full Title: A Phase I/IIa Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL Amyloidosis
    Medical condition: AL-Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10024460 Light chain disease myeloma associated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-019986-27 Sponsor Protocol Number: RESPIRO Start Date*: 2010-06-02
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Breathing disorders in heart failure: high altitude hypoxia as a model to define diagnostic tools, therapeutic strategies and gender related differences.
    Medical condition: Chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019280 HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000928-18 Sponsor Protocol Number: PROMESA Start Date*: 2013-11-21
    Sponsor Name:Hospital of the Ludwig-Maximilians-University of Munich
    Full Title: Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atr...
    Medical condition: Progression of patients with Multiple System Atrophy (MSA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001542-17 Sponsor Protocol Number: T109/2019Xe-SAH Start Date*: 2020-09-17
    Sponsor Name:Timo Laitio
    Full Title: Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage
    Medical condition: Acute rupture of cerebral aneurysm, subarachnoid hemorrhage (SAH), unconsciousness, brain injury.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10008078 Cerebral arterial aneurysm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000764-30 Sponsor Protocol Number: HOT-LOCO Start Date*: 2021-07-06
    Sponsor Name:Karolinska University Hospital
    Full Title: Hyperbaric Oxygen for Treatment of Long COVID syndrome; A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial
    Medical condition: Long COVID, post-acute COVID-19 Syndrome, post COVID-19 Syndrome (ICD-10 U09.0)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    20.1 10021881 - Infections and infestations 10057244 Post viral fatigue syndrome PT
    20.0 10007541 - Cardiac disorders 10063080 Postural orthostatic tachycardia syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000192-86 Sponsor Protocol Number: NMSNabStudy Start Date*: 2017-09-15
    Sponsor Name:Medizinische Universität Innsbruck, Universitätsklinik für Neurologie
    Full Title: Nabilone for non-motor symptoms in Parkinson´s disease: A Randomized Placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal Study
    Medical condition: Subjects with non-motor symptoms of Parkinson´s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004253-16 Sponsor Protocol Number: NMSNab2study Start Date*: 2018-04-13
    Sponsor Name:Medizinische Universität Innsbruck, Universitätsklinik für Neurologie
    Full Title: Nabilone for non-motor symptoms in Parkinson’s disease: An open-label study to evaluate long-term safety and efficacy
    Medical condition: Subject with non-Motor symptoms of Parkinson´s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004565-13 Sponsor Protocol Number: GR-2018-12366771 Start Date*: 2022-09-08
    Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease. A multicenter, randomized, double-blind, placebo-controlled, phase 2 trial.
    Medical condition: Parkinson's disease associated to mutation on the GBA1 gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10042832 Syndrome Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002987-17 Sponsor Protocol Number: ALN-TTR02-004 Start Date*: 2013-11-25
    Sponsor Name:Alnylam Pharmaceuticals, Inc
    Full Title: APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneu...
    Medical condition: Transthyretin mediated amyloidosis (ATTR)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    19.0 10010331 - Congenital, familial and genetic disorders 10019889 Hereditary neuropathic amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) PT (Completed) IT (Completed) DE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000336-28 Sponsor Protocol Number: TAK-341-2001 Start Date*: 2022-10-21
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple...
    Medical condition: Multiple System Atrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003337-15 Sponsor Protocol Number: CLR_18_06 Start Date*: 2019-06-18
    Sponsor Name:Sun Pharma Advanced Research Company (SPARC) Limited
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease
    Medical condition: Early Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-001227-31 Sponsor Protocol Number: NISCI Start Date*: 2019-06-19
    Sponsor Name:University Zurich, University Hospital Balgrist, Spinal Cord Injury Center
    Full Title: Antibodies against Nogo-A to enhance plasticity, regeneration and functional recovery after acute spinal cord injury
    Medical condition: spinal cord injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10041554 Spinal cord injury cervical PT
    20.1 10022117 - Injury, poisoning and procedural complications 10041552 Spinal cord injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 07:19:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA